The new era of cervical cancer prevention: HPV vaccination

Gynecologic Oncology

Volumn 109, Issue 2 SUPPL., 2008, Pages

  Monk, Bradley J ^a   Herzog, Thomas J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; DISEASE ASSOCIATION; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; MORBIDITY; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 43249095049     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.002     Document Type: Editorial

References (13)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (Mar-Apr 2005) 74-108
2. Ries L.A.GM.D., Krapcho M., Mariotto A., Miller B.A., Feuer E.J., Clegg L., et al. Seer Cancer Statistics Review, 1975-2004 (2007), National Cancer Institute, Bethesda, MD Based on November 2006 SEER data submission, posted to the SEER web site
3. American Cancer Society. Cancer Facts & Figures 2007 (2007)
4. Insinga R.P., Dasbach E.J., and Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmaco Economics 23 11 (2005) 1107-1122
5. Mahdavi A., and Monk B.J. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10 7 (Aug 2005) 528-538
6. Monk B.J., and Mahdavi A. Human papillomavirus vaccine: a new chance to prevent cervical cancer. Recent Results Cancer Res 174 (2007) 81-90
7. Centers for Disease Control and Prevention. MMWR Vol 56 (2007) 1-24
8. Merck to donate three million doses of Gardasil, its cervical cancer vaccine, to support vaccination programs in lowest income nations. Available at: http://www.merck.com/newsroom/press_release/product/;2007_0926.html. Accessed November 12th, 2007.
9. Global Health Commitments. Gardasil Access Program. Available at: (. 2007). http://commitments.clintonglobalinitiative.org/projects.htm?mode=view &rid=209717
10. Monk B.J., and Wiley D.J. Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?. Obstet Gynecol 108 2 (Aug 2006) 420-424
11. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (Jun 30 2007) 2161-2170
12. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (May 2005) 271-278
13. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (Nov 13-19 2004) 1757-1765